Literature DB >> 10078486

Influenza-associated morbidity and mortality in young and middle-aged women.

K M Neuzil1, G W Reed, E F Mitchel, M R Griffin.   

Abstract

CONTEXT: Data are limited on rates of influenza-associated hospitalizations and deaths among adults younger than 65 years.
OBJECTIVE: To quantify serious morbidity and mortality from influenza for women younger than 65 years with and without certain chronic medical conditions, including human immunodeficiency virus infection.
DESIGN: Retrospective cohort study. SETTING AND POPULATION: Women aged 15 to 64 years enrolled in the Tennessee Medicaid program from 1974 to 1993. MAIN OUTCOME MEASURE: All hospitalizations for and deaths from pneumonia, influenza, and other selected acute cardiopulmonary conditions for women with and without selected chronic medical conditions during 19 consecutive years. Influenza-attributable risk was calculated by subtracting event rates during peri-influenza season (November through April of each year when influenza virus was not circulating) from adjusted rates during influenza season (November through April when influenza virus was circulating).
RESULTS: During the 19 years of the study, we identified 53607 acute cardiopulmonary hospitalizations and deaths. Rates of such events were consistently higher during influenza seasons than peri-influenza seasons. Among high-risk women, the estimated annual excess was 23 hospitalizations and deaths per 10000 women aged 15 to 44 years and 58 such events per 10000 women aged 45 to 64 years. The estimated annual excess mortality due to influenza was 2 deaths per 10000 high-risk women for both age groups combined. Among women with no identified high-risk conditions, estimated annual excess hospitalizations and deaths were 4 and 6 per 10000 women aged 15 to 44 and 45 to 64 years, respectively.
CONCLUSIONS: Women younger than 65 years with certain chronic medical conditions experience substantial morbidity and mortality from acute cardiopulmonary events during influenza season. More effective targeting of these populations for annual influenza immunization is warranted.

Entities:  

Mesh:

Year:  1999        PMID: 10078486     DOI: 10.1001/jama.281.10.901

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  66 in total

1.  How to treat influenza and colds.

Authors:  M C Kim; N P Lee
Journal:  West J Med       Date:  2000-04

2.  Influenza: New Insights Into an Old Disease.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

3.  The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality.

Authors:  Verena H Menec; Charlyn Black; Leonard MacWilliam; Fred Y Aoki
Journal:  Can J Public Health       Date:  2003 Jan-Feb

Review 4.  Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications.

Authors:  E Hak; Th J M Verheij; D E Grobbee; K L Nichol; A W Hoes
Journal:  J Epidemiol Community Health       Date:  2002-12       Impact factor: 3.710

5.  Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial.

Authors:  Hana M El Sahly; Charles Davis; Karen Kotloff; Jeffery Meier; Patricia L Winokur; Anna Wald; Christine Johnston; Sarah L George; Rebecca C Brady; Corinne Lehmann; Abbie Stokes-Riner; Wendy A Keitel
Journal:  J Infect Dis       Date:  2012-01-24       Impact factor: 5.226

Review 6.  Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature.

Authors:  Anandi N Sheth; Keri N Althoff; John T Brooks
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

7.  Quantifying influenza vaccine efficacy and antigenic distance.

Authors:  Vishal Gupta; David J Earl; Michael W Deem
Journal:  Vaccine       Date:  2006-01-19       Impact factor: 3.641

Review 8.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

9.  Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults.

Authors:  Nancy F Crum-Cianflone; Seunghyun Won; Rachel Lee; Tahaniyat Lalani; Anuradha Ganesan; Timothy Burgess; Brian K Agan
Journal:  Vaccine       Date:  2016-08-28       Impact factor: 3.641

10.  Rituximab-treated patients have a poor response to influenza vaccination.

Authors:  Robert A Eisenberg; Abbas F Jawad; Jean Boyer; Kelly Maurer; Kenyetta McDonald; Eline T Luning Prak; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2012-10-14       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.